Claims for Patent: 7,722,890

Summary for Patent: 7,722,890

Title:	Synthetic anti-Candida albicans oligosaccharide based vaccines
Abstract:	The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic Candida species.
Inventor(s):	Bundle; David R. (Edmonton, CA), Nitz; Mark (Cambridge, MA), Cutler; Jim E. (New Orleans, LA)
Assignee:	Theracarb, Inc. (Calgary, Alberta, CA)
Application Number:	10/512,216
Patent Claims:	1. A synthetic conjugate that is an oligosaceharide selected from the group consisting of [.beta.-D-mannopyranose-(1.fwdarw.2)-.beta.-D-mannopyranose-(1.fwdarw.2)-- .beta.-D-mannopyranose and .beta.-D-mannopyranose-(1.fwdarw.2)-.beta.-D-mannopyranose, wherein each saccharide unit of said oligosaccharide is linked via an inter-glycosidic atom selected from the group consisting of oxygen and sulfur; and wherein the oligosaccharide is covalently conjugated to a protein carrier through a linking group. 2. The conjugate of claim 1, wherein the oligosacehande is .beta.-D-mannopyranose-(1.fwdarw.2)-.beta.-D-mannopyranose-(1.fwdarw.2)-.- beta.-D-mannopyranose. 3. The conjugate of claim 1, wherein the oligosaceharide is .beta.-D-mannopyranose-(1.fwdarw.2)-.beta.-D-mannopyranose. 4. The conjugate of claim 1, wherein at least one inter-glycosidic atom is sulfur. 5. The conjugate of claim 4, wherein the inter-glycosidic atom at a terminal non-reducing end of at least one of the saccharide units is sulfur. 6. The conjugate of claim 1, wherein the linking group is derived from diethyl squarate, polyoxyalkylene, succinic anhydride or maleic anhydride. 7. The conjugate of claim 1, wherein the linking group is derived from a heterobifunctional or homobifunctional cross coupling reagent. 8. The conjugate of claim 1, wherein the linking group is derived from a mammalian lipid mimic or a bacterial lipid mimic wherein the mammalian lipid mimic or a bacterial lipid mimic is functionalized to permit covalent attachment to a protein or peptide carrier. 9. The conjugate of claim 8, wherein the mammalian lipid mimic or a bacterial lipid mimic is selected from the group consisting of sphingosine, a diacyl glycerol, and a diphytanyl ether of glycerol. 10. The conjugate of claim 1, wherein the protein carrier is selected from the group consisting of bovine serum albumin, human serum albumin, tetanus toxoid, a recombinant outer membrane class 3 porin (rPorB) from group B Neisseria meningitidis, and peptide carriers such as PADRE. 11. The conjugate of claim 10, wherein the protein carrier is tetanus toxoid or bovine serum albumin.

Details for Patent 7,722,890

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28